Fintel reports that on April 2, 2025, HC Wainwright & Co. upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) ...

H.C. Wainwright analyst Matthew Caufield raised the firm’s price target on Mineralys Therapeutics (MLYS) to $42 from $30 and keeps a Buy rating ...

Genelux (NASDAQ:GNLX – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a note issued to investors ...

CG Oncology (NASDAQ:CGON – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright ...

H.C. Wainwright upgraded Sarepta (SRPT) to Neutral from Sell with an unchanged price target of $75. The firm cites the stock’s current ...

Fintel reports that on April 1, 2025, HC Wainwright & Co. initiated coverage of Rezolve AI (NasdaqGM:RZLV) with a Buy recommendation. Analyst Price Forecast Suggests 405.79% Upside As of March 19, ...

A webcast replay will be available on the VYNE website for 90 days following the event. About VYNE Therapeutics Inc. VYNE is a clinical-stage biopharmaceutical company focused on developing ...

H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Aptose Biosciences (APTO) to $6 from $2 and keeps a Buy rating on the shares.

Detailed price information for Gryphon Digital Mining Inc (GRYP-Q) from The Globe and Mail including charting and trades.

Fintel reports that on March 27, 2025, HC Wainwright & Co. initiated coverage of RenovoRx (NasdaqCM:RNXT) with a Buy recommendation. As of March 19, 2025, the average one-year price target for ...